Diamyd Medical increases investment in Companion Medical

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today
that Diamyd Medical increases its investment in Companion Medical by USD
150,000. This is done in connection with a financing transaction in which Eli
Lilly invests USD 3 million in Companion.
Diamyd Medical is a shareholder in the medical device company Companion Medical.
Companion has announced that the company has completed a financing transaction
in which Eli Lilly invests USD 3 million in Companion. The funding will be used
to complete Companion’s development of an insulin injector pen connected to a
smartphone app. In connection to this, Diamyd Medical is investing an additional
USD 150,000 in Companion.

Diamyd Medical holds, which was announced in April 2014 when Diamyd Medical made
its initial investment in Companion, distribution rights to Companion’s future
products in the Nordic region.

Diamyd Medical’s shareholding in Companion Medical is after the investment
approximately 8.5 %.

About Companion Medical
Companion Medical, Inc. is a San Diego based medical device company currently
focused on the diabetes space. Companion is developing advanced tools and
technologies for people living with diabetes who require insulin. While insulin
pumps currently offer the best tools available, the vast majority of people with
diabetes either cannot or will not use a pump.  Companion is developing an
innovative solution that combines the best attributes of current solutions with
advanced data management technologies to address the large global market for
insulin delivery systems. Website: www.companion-medical.com

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes and
LADA. The Company’s projects include development of combination regimens with
the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin
-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65,
the active ingredient in the vaccine, for which the last patent expires in 2032.
Additionally, the Company exclusively licenses UCLA patents for using GABA for
the treatment of diabetes and other inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company
Cellaviva AB, which is establishing a Swedish commercial bank for private family
saving of stem cells in umbilical cord blood and other sources of stem cells.
Stem cells can be expected to be used in Personalized Regenerative Medicine
(PRM), for example, to restore beta cell mass in diabetes patients where
autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.